Category: 2024

Ryvu Therapeutics provides an update on RVU120 Phase II program

Read More

Ryvu Therapeutics to Present Phase II Updates on RVU120 at Investor Event on December 12, 2024

Read More

Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)

Read More

Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform

Read More

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Read More

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Read More

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Read More

Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Read More

Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Read More

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

Read More

Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Read More

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Read More

Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update

Read More

Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank  

Read More

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting  

Read More

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Read More

Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML

Read More

Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event

Read More